RESEARCH ARTICLE

Check for updates

Antiproliferative activity of novel isatinyl/indanyl nitrones (INs) as potential spin trapping agents of free radical intermediates†

Loredana Maiuolo, [iD] *[a] Giordana Feriotto, [iD] [b] Vincenzo Algieri, [iD] [a] Monica Nardi, [iD] [ac] Beatrice Russo, [iD] [a] Maria Luisa Di Gioia, [iD] [d] Emilia Furia, [iD] [a] Matteo Antonio Tallarida, [iD] [a] Carlo Mischiati [iD] [e] and Antonio De Nino [iD] *[a]

A series of ketonitrones derived from isatin and indanone (INs) were synthesized and evaluated for their antiproliferative activities against several human cancer cell lines. Then, the antioxidant properties of these substrates were measured by the DPPH test to report their biological activity in terms of their *spin trapping* action. In particular, one substrate has showed very high biological and scavenging activity, probably due to the strong correlation between its spin trapping activity and structure.

Introduction

Small organic molecules have proven to be invaluable tools for investigating biological systems, but there is still much to learn from their use.[1–3]

Nitrones are small molecules that have the general chemical formula X–CH=NO–Y. Their structural nature endows them their "spin-trap" ability for trapping free radical intermediates (R˙), forming stable radical adducts (X–CHR=NO˙–Y).[4] In fact, studies of their spin trapping activity involved the reaction of nitrones with reactive free radicals such as hydroxyl (˙OH), lipid alkoxy (˙OL) or lipid hydroxyperoxyl (˙OOL) radicals, observing the formation of more stable radicals that can be classified and quantified by electron spin resonance (ESR) or electron paramagnetic resonance (EPR) spectroscopy.[5–7]

Considering a) that biological systems may actively produce reactive oxygen species (ROS) and reactive nitrogen species (RNS), b) that specific oxidation products are produced from reactions between biological molecules and ROS or RNS, c) that ROS and RNS play an important role in many pathological diseases, nitrones and, in particular, PBN-nitrones, where X is a phenyl group and Y is a *tert*-butyl group, were recently considered as therapeutics due to their widespread anti-cancer activity.[8,9] The mechanistic basis of their anti-cancer action is not known. It is probable that their ability to scavenge radical intermediates that are produced during disease processes, including cancer, is the basis for their anti-cancer activity.[4] Moreover, their action on important membrane enzymes and as anti-inflammatory agents seems to contribute to the enhancement of their antioxidant activity.

Isatin and oxindole derivatives have found wide application in medicinal chemistry, for example as potential anticonvulsants,[10] cyclin-dependent kinase 2-inhibitors[11] or inhibitors of poxvirus,[12] ectomelia,[13] rhinovirus,[14] HIV-1[15] and corona-virus,[16] the latter responsible for severe acute respiratory syndrome (SARS). Moreover, the insertion of an oxindole nucleus in spiro compounds has recently attracted attention because of their prevalence in various natural products and biologically active molecules.[17] In fact, the key to their activity seems to be the combination of a spiro carbon and a variously substituted oxindole core. Therefore, the oxindole moiety could be considered as a useful tool in drug discovery.

It is generally recognized that incorporating different bioactive scaffolds into one molecule is a powerful strategy to construct substrates with structural novelty and biological potential.[18] In an attempt to generate novel molecular entities with amplified spin trapping and antiproliferative activity on cancer cells, we synthesized some isatin and indanone ketonitrones, combining the simultaneous presence of an oxindole-like ring and a nitrone portion.

[a] Dipartimento di Chimica e Tecnologie Chimiche, Università della Calabria, Via P. Bucci, cubo 12C, 87036 Rende (CS), Italy. E-mail: maiuolo@unical.it, denino@unical.it
[b] Dipartimento di Scienze Chimiche e Farmaceutiche, Università di Ferrara, via L. Borsari 46, 44121 Ferrara, Italy
[c] Dipartimento di Agraria, Università Telematica San Raffaele, Via di Val Cannuta, 247, Roma, 00166, Italy
[d] Dipartimento di Farmacia e Scienze della Salute e della Nutrizione, Edificio Polifunzionale, Università della Calabria, 87036 Rende (CS), Italy
[e] Dipartimento di Scienze Biomediche e Chirurgico Specialistiche, Università di Ferrara, Via L. Borsari 46, 44121 Ferrara, Italy
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7md00537g

Results and discussion

In the literature, a few examples of synthetic procedures for nitrones of oxindole derivatives have been reported thus far.[19–22] Recently, we have realized an environmentally-friendly approach to synthesize aldo- and ketonitrones by solvent-free condensation of alkyl- or arylhydroxylamine hydrochlorides with aromatic aldehydes under microwave irradiation.[23]

Herein, we report the practical and stereoselective synthesis of isatinyl and indanyl nitrones (INs) obtained from substituted hydroxylamines **1a–c** and isatin derivatives **2a–c** or indanones **3a–b**, as shown in Table 1. Then, we investigated the antiproliferative activity of these substrates on MG63 and TE85 human osteosarcoma cell lines and the K562 human erythroleukemic cell line; next we sought to correlate it with their antioxidant properties measured by the DPPH assay.

The target compounds **4a–e** and **5a–c** were prepared by following our previously reported methodology[23] which consists of co-grinding the ketone and hydroxylamine in a mortar, followed by transferring the mixture without the use of solvent in an appropriate vessel and further mixing of the solids in a vortex mixer. Finally, the mixture is placed in a microwave oven without the use of solvent and is irradiated at 600 W or 400 W for variable time periods in the order of minutes.

The variously substituted products **4a–e** and **5a–c** were obtained in high yields (83–95%). The low reactivity of the indanone ring prompted us to reduce the MW power and to increase the reaction time. In all cases, nitrones were obtained as single isomers, (*E*) **4a–e** and (*Z*) **5a–c**, respectively, as confirmed by NOESY experiments. In particular, for nitrone **4b**, the formation of only a single product, the *E*-isomer, is observed with respect to *Z*/*E* mixtures obtained by other synthetic methodologies.[24]

In an attempt to understand the molecular characteristics and the effects produced by the modifications introduced into our nitrones on tumour cell proliferation, the nitrones prepared according to this procedure were evaluated for their antiproliferative activity against human osteosarcoma (MG63 and TE85)[25] and chronic myeloid leukemia (K562)[26] cell lines. Cells were cultured for three days in the absence or in the presence of increasing concentration of nitrones and then their viability was evaluated by analyzing the activity of the oxidative metabolism by the 3-(4,5- dimethylthiazolyil-2)-2,5-diphenyltetrazolium bromide (MTT) assay.[27] In Fig. 1, the proliferation of the treated cells was expressed as percentage compared to untreated control cells.

The data indicated that not all the nitrones had antiproliferative activity, since compounds **5a–c** and **4b** were completely inactive. Compounds **4c–e** inhibited the


Fig. 1 Effect of nitrones **4a–e** and **5a–c** on cell proliferation. MG63 (A), TE85 (B) and K562 (C) cells were incubated for three days in the presence of the indicated compounds. Viable cells were measured by the MTT test and reported as % relative to untreated control. The arithmetic mean value ± standard deviation of three experiments performed in triplicate is shown.

Table 1 Synthesis of isatinyl and indanyl nitrones

Entry	R	R^1	Y	X	MW (W)	Time (min)	Product	Yield (%)
1	Me	5-NO$_2$	NH	CO	600	10	**4a**	95
2[a]	Ph	H	NH	CO	600	10	**4b**	92
3	Bn	5-NO$_2$	NH	CO	600	13	**4c**	92
4	Bn	H	NH	CO	600	12	**4d**	95
5	Bn	H	NMe	CO	600	12	**4e**	92
6	Me	H	CH$_2$	CH$_2$	400	30	**5a**	82
7	Me	5-F	CH$_2$	CH$_2$	400	28	**5b**	83
8	Bn	H	CH$_2$	CH$_2$	400	30	**5c**	85

[a] A ketone/alkylhydroxylamine ratio of 1:2 for all substrates except for entry 2 with a ratio of 1:3.

proliferation of osteosarcoma MG63 cells compared to untreated cells (Fig. 1A, IC$_{50}$ about 77 μM).

In Fig. 1B, the antiproliferative activities of nitrones **4a** and **4c–d** on TE85 cells (IC$_{50}$ about 32 μM) are shown. The active compounds are less effective in inhibiting the proliferation of K562 cells, with the exception of nitrone **4e** with an IC$_{50}$ of about 78 μM (Fig. 1C). Together, these results have shown that the indanyl derivatives do not possess antiproliferative activity on the tumour cells analyzed, as well as the derivative **4b** with the phenyl substituent. By contrast, isatinyl nitrones containing methyl or benzyl groups possess antiproliferative activity.

The *in vitro* antioxidant activity of these ketooxindole nitrones (**4a–e** and **5a–c**) was evaluated by using the stable organic free radical DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity assay.[28–31]

In Scheme 1, the reaction mechanism for the spin-trapping action of nitrones **4a–e** and **5a–c** with a generic free radical (including the DPPH radical) is illustrated, according to the literature.[32] It can be noted from the scheme below that the reaction produces the highly stable nitroxyl radical **6**.[33,34]

When DPPH reacts with a radical scavenger, its maximum absorbance decreases. A freshly prepared DPPH solution displayed a deep purple colour with the absorption maximum at 517 nm. The ethanolic solution of DPPH was added to the solution of the synthesized compounds in ethanol. After 10 min of incubation in the dark, the absorbance was measured by using absolute ethanol as blank. BHT (butylated hydroxytoluene) was used as reference. In the presence of an antioxidant, the DPPH absorbance decreases. The antioxidant activity was calculated as radical scavenging activity (RSA%) as expressed in eqn (1):

$$RSA\% = [(A_0 - A_i)/A_0] \times 100 \qquad (1)$$

where A_0 and A_i are the DPPH absorbance at 517 nm in the absence and presence of the synthesized compounds, respectively. The RSA% for ketonitrones **4a–e** and **5a–c** at five different concentrations (*i.e.*, 1.15, 2.45, 4.00, 6.25 and 9.10 × 10^{-6}

mol L^{-1}) of the tested compounds with DPPH at 517 nm is reported in Table 2.

As can be seen in Table 2, all the compounds exhibited antioxidant activity. The substances can be divided into three main groups. The first group is composed of two substances (**4c** and **4e**) with higher values of antioxidant activity than others. In particular, the highest values were observed for **4e**, for which the RSA% is equal to 60% at a concentration of 2.45 × 10^{-6} mol L^{-1}.

Four substances compose the second group with intermediate antioxidant activity (**4a–b**, **5a** and **5c**). For all of these compounds, the RSA% was higher than 60% at a concentration equal to 6.25 × 10^{-6} mol L^{-1}. In the third group, only two compounds with lower antioxidant activity were included: **4d** and **5b**. For these last two compounds, the RSA% was 80% at a concentration equal to 9.10 × 10^{-6} mol L^{-1}. As can be seen in Table 2 and Fig. 2, all nitrones **4a–e** and **5a–c** exhibited a radical scavenging activity significantly higher than that of the reference (BHT). We have not investigated concentrations higher than 9.10 × 10^{-6} mol L^{-1} as the RSA% trend reaches a plateau.

The RSA% of nitrones **4a–e** and **5a–c** may be compared with the value of archetypal (Z) α-phenyl-*N-tert*-butyl nitrone (PBN) reported in the literature.[35] Its RSA% is 1.4 ± 0.9 at a concentration of 0.5 × 10^{-3} mol L^{-1} calculated through the DPPH test, demonstrating antioxidant properties significantly lower with respect to those of our nitrones.

For all the tested compounds, the EC$_{50}$ values were also calculated by using the GraphPad Prism 5.01 program, as reported in the literature (Table 2).[36] The EC$_{50}$ is the antioxidant concentration required to obtain 50% radical inhibition. As can be seen in Table 2 the EC$_{50}$ values of all eight synthesized nitrones are higher than that of the reference substance (BHT).

The antioxidant properties of INs seem to agree quite well with the biological results, confirming the importance of the isatinyl ring. In particular, the presence of both aromatic systems and electron-donating groups (*e.g.* methyl group) improves the performance, as can particularly be seen for substrate **4e**.

Experimental

Commercial starting materials were used without further purification. Reactions were monitored by TLC using 60-F264 silica plates, commercially available from Merck. ^{1}H and ^{13}C NMR spectra were recorded at 300 MHz and 75 MHz, respectively, in CDCl$_3$ and DMSO-d$_6$ using tetramethylsilane (TMS) as an internal standard (Bruker ACP 300 MHz). Chemical shifts are given in parts per million and coupling constants in Hertz. The stereochemistry was established by NOESY experiments. Purity was verified by NMR and HPLC.

LC-MS analysis was carried out using an Agilent 6540 UHD Accurate – Mass Q-TOF LC-MS (Agilent, Santa Clara, CA) equipped with an electrospray ionisation source (Dual AJS ESI) operating in positive ion mode. Chromatographic

Scheme 1 Reaction mechanism of nitrones **4a–e** and **5a–c** with free radicals.

Table 2 Percentage of *in vitro* radical scavenging activity of INs

| Compounds | Concentrations (10^{-6} mol L^{-1}) | | | | | |
	1.15	2.45	4.00	6.25	9.10	EC$_{50}$
4a	—	—	1.1 ± 0.5	72 ± 2	79 ± 2	1.2 ± 0.2
4b	1.1 ± 0.5	1.2 ± 0.5	1.2 ± 0.5	69 ± 2	80 ± 2	1.3 ± 0.2
4c	—	—	60 ± 1	67 ± 2	80 ± 2	1.0 ± 0.2
4d	1.1 ± 0.5	1.1 ± 0.5	1.2 ± 0.5	1.2 ± 0.5	78 ± 2	1.8 ± 0.1
4e	1.2 ± 0.5	60 ± 1	68 ± 2	70 ± 2	79 ± 2	0.6 ± 0.3
5a	—	—	1.1 ± 0.5	60 ± 1	78 ± 2	1.3 ± 0.2
5b	—	—	1.1 ± 0.5	1.2 ± 0.5	79 ± 2	1.8 ± 0.1
5c	1.1 ± 0.5	1.2 ± 0.5	1.3 ± 0.5	70 ± 2	79 ± 2	1.2 ± 0.2
BHT	—	4.6 ± 0.5	11.7 ± 0.5	23.0 ± 0.5	27.0 ± 0.5	3.8 ± 0.5

separation was achieved using a C18 RP analytical column (Poroshell 120, SB-C18, 50 × 2.1 mm, 2.7 μm) at 30 °C with an elution gradient from 5% to 95% of B over 13 min., A being H_2O (0.1% FA) and B CH_3CN (0.1% FA). The flow rate was 0.4 ml min^{-1}.

MW-assisted reactions were performed on a Synthos 3000 instrument from Anton Paar, equipped with a 4x24MG5 rotor and an IR probe as an external control of the temperature. 0.3–3 mL glass vials sealed with a dedicated PEEK screw-cup together with a reliable PTFE seal were used for all reactions. In the synthesis of all the derivatives, the temperature was always maintained at 180 °C in each experiment, except for **5a–c** where the temperature was always maintained at 125 °C.

General procedure for synthesis of nitrones 4a–e and 5a–c

The selected ketone (0.50 g) and appropriate hydroxylamine derivative (2 eq. or 3 eq. for *N*-phenylhydroxylamine) were ground in a mortar, placed in an appropriate vessel and mixed using a vortex mixer. The mixture was transferred to a microwave oven and irradiated with suitable power. After the appropriate time, the crude oil was recrystallized with ethyl acetate (**4a–e**) or cyclohexane (**5a–c**).

(E)-N-(5-Nitro-2-oxoindolin-3-ylidene)methanamine oxide 4a

Yellow solid, 95% yield, (0.52 g). ^{1}H NMR (300 MHz, DMSO-d$_6$): 4.28 (s, 3H, CH$_3$), 7.02 (d, *J* = 8.73 Hz, 1H, Ar), 8.23 (d, *J* = 8.73 Hz, 1H, Ar), 8.75 (s, 1H, Ar), 11.53 (s, 1H, NH), ^{13}C NMR

**Fig. 2** Graphical presentation of *in vitro* DPPH radical scavenging activity of compounds relative to the standard antioxidant BHT.

(75 MHz, DMSO-d$_6$): δ 51.8, 110.2, 118.7, 118.7, 128.0, 133.3, 142.4, 145.2, 161.9. ESI (+)-MS: *m/z* [M + H] calcd for C$_9$H$_8$N$_3$O$_4$ 222.0515, found: 222.0503.

(E)-N-(2-Oxoindolin-3-ylidene)aniline oxide 4b

Orange red solid, 92% yield, (0.74 g). ^{1}H NMR (300 MHz, DMSO-d$_6$): 6.85 (d, *J* = 7.80 Hz, 1H, Ar), 7.15 (t, *J* = 7.65 Hz, 1H, Ar), 7.40 (t, *J* = 7.80 Hz, 1H, Ar), 7.45–7.65 (m, 5H, Ar), 8.27 (d, *J* = 7.65 Hz, 1H, Ar), 10.78 (s, 1H, NH), ^{13}C NMR (75 MHz, DMSO-d$_6$): δ 109.7, 118.4, 121.7, 123.9, 124.1, 128.7, 130.1, 132.2, 134.4, 140.9, 146.3, 159.9. ESI (+)-MS: *m/z* [M + H] calcd for C$_{14}$H$_{11}$N$_2$O$_2$ 239.0821, found: 239.0817.

(E)-N-(5-Nitro-2-oxoindolin-3-ylidene)-1-phenylmethanamine oxide 4c

Yellow solid, 92% yield (0.64 g). ^{1}H NMR (300 MHz, DMSO-d$_6$): 5.91 (s, 2H, CH$_2$), 7.07 (d, *J* = 8.73 Hz, 1H, Ar), 7.31–7.58 (m, 5H, Ar), 8.28 (dd, *J* = 2.43 Hz, 8.73 Hz, 1H, Ar), 8.84 (d, *J* = 2.43 Hz, 1H, Ar), 11.70 (s, 1H, NH) ^{13}C NMR (75 MHz, DMSO-d$_6$): δ 65.6, 110.4, 118.8, 119.0, 128.3, 129.1, 129.1, 129.6, 133.2, 134.1, 142.6, 145.4, 161.9. ESI (+)-MS: *m/z* [M + H] calcd for C$_{15}$H$_{12}$N$_3$O$_4$ 298.0828, found: 298.0816.

(E)-N-(2-Oxoindolin-3-ylidene)-1-phenylmethanamine oxide 4d

Orange solid, 95% yield (0.80 g). ^{1}H NMR (300 MHz, DMSO-d$_6$): δ 5.89 (s, 2H, CH$_2$Bn), 6.91 (d, *J* = 7.78 Hz, 1H, Ar), 7.10 (dt, *J* = 0.91, 7.65 Hz, 1H, Ar), 7.25–7.54 (m, 6H, Ar), 8.12 (d, *J* = 7.65 Hz, 1H, Ar), 11.01 (s, 1H, NH), ^{13}C NMR (75 MHz, DMSO-d$_6$): δ 64.3, 109.8, 118.1, 122.04, 123.9, 128.5, 129.6, 129.1, 131.8, 133.4, 134.2, 139.6, 161.2. ESI (+)-MS: *m/z* [M + H] calcd for C$_{15}$H$_{13}$N$_2$O$_2$ 253.0977, found: 253.0977.

(E)-N-(1-Methyl-2-oxoindolin-3-ylidene)-1-phenylmethanamine oxide 4e

Yellow solid, 92% yield (0.76 g). ^{1}H NMR (300 MHz, DMSO-d$_6$): 3.25 (s, 3H, CH$_3$), 5.92 (s, 2H, CH$_2$), 7.08 (t, *J* = 8.26 Hz, 2H, Ar), 7.37–7.50 (m, 6H, Ar), 8.15 (d, *J* = 7.34 Hz, 1H, Ar), ^{13}C NMR (75 MHz DMSO-d$_6$): δ 26.6, 65.2, 109.2, 117.8, 123.1, 124.0, 129.0, 129.0, 129.59, 132.2, 134.6, 141.5, 160.4. ESI (+)-MS: *m/z* [M + H] calcd for C$_{16}$H$_{15}$N$_2$O$_2$ 267.1134, found: 267.1126.

(Z)-N-(2,3-Dihydro-1H-inden-1-ylidene)methanamine oxide 5a

White solid, 82% yield (0.50 g). ^{1}H NMR (300 MHz, CDCl$_3$): δ 2.90–3.05 (m, 2H, CH$_2$), 3.11–3.22 (m, 2H, CH$_2$), 3.81 (s, 3H, CH$_3$), 7.29–7.44 (m, 3H, Ar), 8.84 (d, J = 7.81 Hz, 1H, Ar), ^{13}C NMR (75 MHz, CDCl$_3$): δ 28.7, 29.4, 49.6, 124.5, 127.0, 131.0, 134.4, 147.8, 149.7. ESI (+)-MS: m/z [M + H] calcd for C$_{10}$H$_{12}$NO 162.0919, found: 162.0912.

(Z)-N-(5-Fluoro-2,3-dihydro-1H-inden-1-ylidene)methanamine oxide 5b

White solid, 83% yield (0.48 g). ^{1}H NMR (300 MHz, CDCl$_3$): δ 3.01 (dd, J = 5.43 Hz, 11.73 Hz, 2H, CH$_2$), 3.14 (dd, J = 5.55 Hz, 11.97 Hz, 2H, CH$_2$), 6.80–7.12 (m, 2H, Ar), 8.86 (dd, J = 5.79 Hz, 8.64 Hz, 1H, Ar), ^{13}C NMR (75 MHz, CDCl$_3$): δ 28.8 (d, JCF = 2.28), 29.9, 49.6, 111.9 (d, J2CF = 23.02), 114.3 (d, J2CF = 22.86), 128.8 (d, J3CF = 9.03), 130.9 (d, J4CF = 2.02), 148.1, 150.5 (d, J3CF = 8.95), 164.43 (d, J1CF = 250.96). ESI (+)-MS: m/z [M + H] calcd for C$_{10}$H$_{11}$FNO 180.0825, found: 180.0818.

(Z)-N-(2,3-Dihydro-1H-inden-1-ylidene)-1-phenylmethanamine oxide 5c

White solid, 85% yield (0.76 g). ^{1}H NMR (300 MHz, CDCl$_3$): δ 2.91–3.09 (m, 2H, CH$_2$), 3.10–3.23 (m, 2H, CH$_2$), 5.11 (s, 2H, CH$_2$Bn), 7.21–7.45 (m, 7H, Ar), 7.51 (d, J = 7.16 Hz, 1H, Ar), 8.92 (d, J = 7.63 Hz, 1H, Ar), ^{13}C NMR (75 MHz, CDCl$_3$): δ 29.0, 29.2, 66.6, 124.5, 127.1, 127.2, 128.2, 128.3, 128.9, 131.1, 133.4, 134.8, 147.7, 149.1. ESI (+)-MS: m/z [M + H] calcd for C$_{16}$H$_{16}$NO 238.1232, found: 238.1230.

Antiproliferative activity evaluation

Human cell lines were obtained from ATCC (Manassas, VA). MG63 (CRL-1427) and HOS TE85 (CRL-1543) osteosarcoma cells were maintained in DMEM, while K562 (CCL-243) chronic myeloid leukemia cells in RPMI 1640. The culture medium was supplemented with 10% fetal bovine serum, penicillin (100 U mL^{-1}), streptomycin (100 U mL^{-1}) and glutamine (2 mM); incubation was conducted at 37 °C in a 5% CO$_2$ atmosphere. Compounds were solubilized in 40 mM DMSO, kept at −80 °C in the dark and diluted in complete medium immediately before use. The osteosarcoma cells were seeded at 4000 cells per well in a 96-well plate 6 hours before the treatment. The leukemia cells were seeded at 20 000 cells per mL. Cells were treated with the test compounds at concentrations ranging from 3 to 200 µM. Untreated cells were placed in every plate as negative control. After 3 days of culture, the inhibitory effect on cell proliferation was analysed by addition of 25 µL MTT (thiazolyl blue) staining solution, in which metabolically active cells convert the yellow tetrazolium salt to purple formazan crystals providing a quantitative determination of viable cells. Two hours later, formazan crystals were solubilized in 100 µL of lysing buffer (50% DMF + 20% SDS, pH 4.7) for 16 hours, whereupon the spectrophotometric absorbance at 570 nm was measured. The half maximal inhibitory concentration (IC$_{50}$) was calculated using Scientist

software. Three independent experiments were performed in triplicate.

Antioxidant evaluation

The free radical scavenging activity against DPPH was determined at five different concentrations according to a previous work.[28] Thus, EtOH solutions containing known amounts of the compounds (4a–e and 5a–c) and of DPPH were prepared in a range of concentrations from 1.15×10^{-6} to 9.10×10^{-6} mol L^{-1} (Table 2). A decrease in the absorbance of DPPH was measured at 517 nm, against ethanol as blank, by using a UV-vis spectrophotometer (Varian Cary 50 Scan), after a period of 10 min since preparation. Experiments were carried out in triplicate and BHT (butylated hydroxytoluene) was used, in the same concentration range of the compounds, as the reference antioxidant.

Conclusions

In summary, a series of isatinyl/indanyl nitrones (INs) were synthesized and their antiproliferative activity on MG63, TE85 and K562 cells was determined. Derivatives with the isatin ring showed the highest activity, while the indanone nitrones were practically inactive. Then the antioxidant activities were evaluated through the DPPH test. The results indicated that all compounds are markedly more active than the reference compound BHT. Among them, nitrone **4e** exhibits the most potent antioxidant activity at low concentration and its *spin-trap* action matches perfectly with its antiproliferative effect on cancer cells. Collectively, the current study may provide a new insight into the treatment of degenerative diseases such as cancer.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Notes and references

1 B. R. Stockwell, *Nature*, 2004, **432**(7019), 846.

2 E. Furia and R. Porto, *J. Chem. Eng. Data*, 2008, **53**(12), 2739.

3 E. Furia, A. Napoli, A. Tagarelli and G. Sindona, *J. Chem. Eng. Data*, 2013, **58**(5), 1349–1353.

4 R. A. Floyd, H. K. Chandru, T. He and R. Towner, *Anti-Cancer Agents Med. Chem.*, 2011, **11**(4), 373–379.

5 G. M. Rosen, M. S. Cohen, B. E. Britigan and S. Pou, *Free Radical Res. Commun.*, 1990, **9**, 187–195.

6 A. Tomasi and A. Iannone in ESR spin trapping artifacts in biological model systems, *EMR of Paramagnetic Molecules*, ed. L. J. Berliner and J. Reuben, Plenum Press, New York, 1993, pp. 353–354.

7 C. J. Rhodes, in *Toxicology of the Human Environment, The Critical Role of Free Radicals*, Taylor & Francis, New York, 2000.

8 R. A. Floyd, R. D. Kopke, C.-H. Choi, S. B. Foster, S. Doblas and R. A. Tower, *Free Radical Biol. Med.*, 2008, **45**(10), 1361–1374, 15.

9 R. A. Floyd, R. A. Towner, D. Wu, A. Abbott, R. Cranford, D. Branch, W.-X. Guo, S. B. Foster, I. Jones, R. Alam, D. Moore, T. Allen and M. Huycke, *Free Radical Res.*, 2010, **44**(1), 108–117.

10 M. Verma, S. N. Pandeya, K. N. Singh and J. P. Stables, *Acta Pharm.*, 2004, **54**, 49.

11 H. N. Bramson, J. Corona, S. T. Davis, S. H. Dickerson, M. Edelstein, S. V. Frye, R. T. Gampe Jr., P. A. Harris, A. Hassell, W. D. Holmes, R. N. Hunter, K. E. Lackey, B. Lovejoy, M. J. Luzzio, V. Montana, W. J. Rocque, D. Rusnak, L. Shewchuk, J. M. Veal, D. H. Walker and L. F. Kuyper, *J. Med. Chem.*, 2001, **44**, 4339.

12 M. C. Pirrung, S. V. Pansare, K. D. Sarma, K. A. Keith and E. R. Kern, *J. Med. Chem.*, 2005, **48**, 3045.

13 D. J. Bauer and P. W. Sadler, *Nature*, 1961, **190**, 1167.

14 J. M. Z. Gladych, J. H. Hunt, D. Jack, R. F. Haff, J. J. Boyle, R. C. Stewart and R. Ferlauto, *J. Nat.*, 1969, **221**, 286.

15 D. Sriram, T. R. Bal and P. Yogeeswari, *J. Pharm. Pharm. Sci.*, 2005, **8**, 565.

16 L. Zhou, Y. Liu, W. Zhang, P. Wei, C. Huang, J. Pei, Y. Yuan and L. Lai, *J. Med. Chem.*, 2006, **49**, 3440.

17 B. Yu, D.-Q. Yu and H.-M. Liu, *Eur. J. Med. Chem.*, 2015, **97**, 673–698.

18 L. Maiuolo, O. Bortolini, A. De Nino, B. Russo, R. Gavioli and F. Sforza, *Aust. J. Chem.*, 2014, **67**, 670.

19 H.-B. Yang and S. Min, *Org. Biomol. Chem.*, 2012, **10**, 8236.

20 H. G. Aurich and W. Weiss, *Tetrahedron*, 1976, **32**, 159.

21 S. Y. Wu, X.-P. Ma, C. Liang and D.-L. Mo, *J. Org. Chem.*, 2017, **82**, 3232–3238.

22 Y.-H. Zhang, M.-Y. Wu and W.-C. Huang, *RSC Adv.*, 2015, **5**, 105825.

23 L. Maiuolo, A. De Nino, P. Merino, B. Russo, G. Stabile, M. Nardi, N. D'Agostino and T. Bernardi, *Arabian J. Chem.*, 2016, **9**, 25.

24 S.-Y. Wu, X.-P. Ma, C. Liang and D.-L. Mo, *J. Org. Chem.*, 2017, **82**(6), 3232–3238.

25 B. Fuchs, E. Mahlum, C. Halder, A. Maran, M. Yaszemski, B. Bode, M. Bolander and G. Sarkar, *Gene*, 2007, **399**, 137.

26 G. Feriotto, R. Calza, C. M. Bergamini, M. Griffin, Z. Wang, S. Beninati, V. Ferretti, E. Marzola, R. Guerrini, A. Pagnoni, A. Cavazzini, F. Casciano and C. Mischiati, *Amino Acids*, 2017, **49**, 551.

27 O. Bortolini, A. De Nino, T. Eliseo, R. Gavioli, L. Maiuolo, B. Russo and F. Sforza, *Bioorg. Med. Chem.*, 2010, **18**, 6970.

28 M. Kaur, B. Singh, B. Singh and A. Arjuna, *J. Heterocycl. Chem.*, 2017, **54**, 1348.

29 A. Fazio, M. C. Caroleo, E. Cione and P. Plastina, *Food Packaging and Shelf Life*, 2017, **11**, 84.

30 A. Fazio, D. Terenzio, A. Piccinelli and L. Rastrelli, *Pharmacologyonline*, 2014, **2**, 1.

31 H. Petkes, E. Gal, C. Bischin, I. Lupan, C. Majdik, C. Cristea and L. Silaghi-Dumitrescu, *Rev. Roum. Chim.*, 2015, **60**, 7–8, 659.

32 E. G. Janzen, *Acc. Chem. Res.*, 1971, **4**(1), 31.

33 R. I. Zhdanov, in *Bioactive Spin Labels*, Springer-Verlag, Berlin, Heidelberg, 1992.

34 C. L. Hawkins and M. J. Davies, *Biochim. Biophys. Acta*, 2014, **1840**, 708.

35 A. Samadi, E. Soriano, J. Revuelta, C. Valderas, M. Chioua, I. Garrido, B. Bartolomé, I. Tomassolli, L. Ismaili, L. González-Lafuente, M. Villarroya, A. G. García, M. J. Oset-Gasque and J. Marco-Contelles, *Bioorg. Med. Chem.*, 2011, **19**, 951.

36 Z. Chen, R. Bertin and G. Froldi, *Food Chem.*, 2013, **138**, 414.